2.2. Pharmacokinetics
The pharmacokinetics of semisynthetic derivatives of PPT depends on the
hydrophobicity of the molecule. PPT has reportedly been given to the
patient as a 30 minutes infusion in skin cancer treatment or via direct
application of the cream/solution to the lesion
(Ardalani et al., 2017;
Lacey et al., 2003). The maximum
tolerated dose (MTD) is 120 mg/m2 in human beings, and
elimination half-life is up to 5 hours depending on the derivative
(Frazier and Price, 2010;
Smyth et al., 1985). Clinical studies
showed that dermal absorption of this drug is limited, and its
metabolism takes place in the liver and kidneys.